Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis

Azzopardi, L., Thompson, S. A. J., Harding, Katharine, Cossburn, M., Robertson, Neil ORCID: https://orcid.org/0000-0002-5409-4909, Compston, A., Coles, A. J. and Jones, J. L. 2014. Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 85 (7) , pp. 795-98. 10.1136/jnnp-2013-307042

Full text not available from this repository.

Abstract

Objective We have previously shown that autoimmunity following alemtuzumab treatment of multiple sclerosis can be predicted by high baseline serum interleukin IL-21 (IL-21), as measured using a now ‘redundant’ enzyme linked immunosorbent assay (ELISA). Here we ask whether currently available ELISAs have similar prognostic value. Design Serum IL-21 from 141 individuals with relapsing remitting multiple sclerosis was measured using the now ‘redundant’ IL-21 ELISA and five further currently available kits. All patients had been treated with alemtuzumab; 61/141 had developed secondary autoimmunity. Results The ‘redundant kit’, and one current kit, confirmed higher baseline serum IL-21 in patients with autoimmunity (542 pg/mL vs. 222 pg/mL and 53.1 pg/mL vs. 9.3 pg/mL respectively) and showed positive correlation. However, only the ‘redundant’ kit had predictive utility. Conclusions Currently available IL-21 ELISA kits should not be used to counsel individuals with multiple sclerosis considering treatment with alemtuzumab.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	BMJ Publishing Group
ISSN:	0022-3050
Last Modified:	28 Oct 2022 09:45
URI:	https://orca.cardiff.ac.uk/id/eprint/75624

Citation Data

Cited 43 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item